QRXPharma writes off
Thursday, 21 August, 2008
QRxPharma (ASX: QRX) has had to write off $18 million in impairment charges this financial year, resulting in a $36 million deficit in the Brisbane-based company's bottom line.
The company accrued $18.1 million in non-cash impairment charges relating to intellectual property licensed from the University of Alabama.
Share based payment charges also accounted for $3.5 million of the deficit.
The remainder of the deficit is in line with QRxPharma's expectations, and has gone towards commercialising the company's Q8004IR dual-opioid oral analgesic, the company said.
The product is expected to be launched in 2010.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
